Radiotherapy was associated with longer survival in metastatic cervical cancer
Adding radiotherapy to systemic treatment was associated with longer overall and progression-free survival without significantly higher acute toxicity.
Adding radiotherapy to systemic treatment was associated with longer overall and progression-free survival without significantly higher acute toxicity.
A nodal-to-primary tumor volume ratio of at least 15% was associated with lower three-year distant metastasis-free survival after extended-field radiotherapy.
Mean treated-breast displacement was 1.6 mm, with larger patient-specific changes near treatment completion and during follow-up.
A 3D-printed jig delivered approximately uniform iridium-192 tumor dose, delayed tumor growth, and caused no observable short-term radiation toxicity in mice.
Hybrid phase-amplitude gating restored dose agreement during regular motion, while irregular breathing increased treatment time and produced inconsistent accuracy.
Off-axis beam optimization preserved target coverage while reducing lung dose and enabling collision-free beam geometry for posterior lung lesions.
Oxygen-ion irradiation showed higher biological effectiveness and more persistent DNA damage than carbon ions or photons in pancreatic cancer cells.
Splitting eight fractions between inhale and exhale breath-holds reduced maximum rib dose from 67.9 to 33.5 Gy without compromising target coverage.
Robust optimization preserved target coverage while reducing lung, heart, esophageal, spinal cord, and estimated immune-cell dose during long-course lung radiotherapy.
Multimodal registration, motion management, and arrhythmia substrate definition were the highest-risk steps in stereotactic arrhythmia radioablation.
A 40 Gy equivalent dose to at least 18% of the left anterior descending artery was associated with more than twofold risk of cardiac events.
The neural model reduced phase-space storage from 3 gigabytes to 600 kilobytes while maintaining at least 89.9% gamma passing at 1%/1 mm.
Definitive intensity-modulated radiotherapy alone achieved 93.0% three-year overall survival, with no recurrence solely within omitted prophylactic nodal regions.
The framework achieved 85.5% external-validation accuracy and reduced estimated review time from 822 hours to 2.3–4.8 hours.
Weekly cisplatin remained non-inferior to three-weekly cisplatin at five years in postoperative high-risk head and neck chemoradiotherapy.